Langenbeck’s Archives of Surgery

, Volume 386, Issue 8, pp 570–574

NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer

Results of a phase II trial

Authors

  • Frank Gansauge
    • Department of General Surgery, University of Ulm
  • Marco Ramadani
    • Department of General Surgery, University of Ulm
  • Jochen Pressmar
    • Department of General Surgery, University of Ulm
  • Susanne Gansauge
    • bio.Venture Technologies, Rechbergweg 31, 89075 Ulm
  • Bernd Muehling
    • Department of General Surgery, University of Ulm
  • Kerstin Stecker
    • Department of General Surgery, University of Ulm
  • Gregor Cammerer
    • Department of General Surgery, University of Ulm
  • Gerd Leder
    • Department of General Surgery, University of Ulm
  • Hans G. Beger
    • Department of General Surgery, University of Ulm
Original Article

DOI: 10.1007/s00423-001-0267-5

Cite this article as:
Gansauge, F., Ramadani, M., Pressmar, J. et al. Langenbeck’s Arch Surg (2002) 386: 570. doi:10.1007/s00423-001-0267-5

Abstract

Background: NSC-631570 (Ukrain) is a semisynthetic compound of thiophosphoric acid and the alkaloid chelidonine from the plant Chelidonium majus. It has been used in complementary herbal medicine for more than 20 years for the treatment of benign and malignant tumors. Patients/methods: Between August 1999 and June 2001, 90 patients with histologically proven unresectable pancreatic cancer were randomized in a monocentric, controlled, randomized study. Patients in arm A received 1000 mg gemcitabine/m2, those in arm B received 20 mg NSC-631570, and those in arm C received 1000 mg gemcitabine/m2 followed by 20 mg NSC-631570 weekly. End point of the study was overall survival. Results: In all three arms therapy was well tolerated and toxicity was moderate. At the first re-evaluation in arm A 32%, in arm B 75%, and in arm C 82% showed no change or partial remission according to WHO criteria (arm A versus arm B: P<0.01, arm A versus arm C: P<0.001). Median survival according to Kaplan-Meier analysis was in arm A 5.2 months, in arm B 7.9 months, and in arm C 10.4 months (arm A versus arm B: P<0.01, arm A versus arm C: P<0.01). Actuarial survival rates after 6 months were 26%, 65% and 74% in arms A B and C, respectively (arm A versus arm B: P<0.05, arm A versus arm C P<0.01). Conclusion: We could show that in unresectable advanced pancreatic cancer, NSC-631570 alone and in combination with gemcitabine nearly doubled the median survival times in patients suffering from advanced pancreatic cancer.

Pancreatic cancer Chemotherapy Gemcitabine NSC-631570 Ukrain

Copyright information

© Springer-Verlag 2002